These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28992626)

  • 1. Multiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Review.
    Lecat M; Decavel P; Magnin E; Lucas B; Gremeaux V; Sagawa Y
    Eur Neurol; 2017; 78(5-6):272-286. PubMed ID: 28992626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Filli L; Zörner B; Kapitza S; Reuter K; Lörincz L; Weller D; Sutter T; Killeen T; Gruber P; Petersen JA; Weller M; Linnebank M
    Neurology; 2017 Feb; 88(9):832-841. PubMed ID: 28148629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Rodriguez-Leal FA; Haase R; Thomas K; Eisele JC; Proschmann U; Schultheiss T; Kern R; Ziemssen T
    Mult Scler; 2018 Sep; 24(10):1337-1346. PubMed ID: 28741976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
    Filli L; Werner J; Beyer G; Reuter K; Petersen JA; Weller M; Zörner B; Linnebank M
    Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A guide to treating gait impairment with prolonged-release fampridine (Fampyra
    Ramió-Torrentà L; Álvarez-Cermeño JC; Arroyo R; Casanova-Estruch B; Fernández O; García-Merino JA; Hernández MA; Izquierdo G; Martínez-Yélamos S; Meca J; Moral E; Olascoaga J; Prieto JM; Saiz A
    Neurologia (Engl Ed); 2018 Jun; 33(5):327-337. PubMed ID: 26873645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fampridine and multiple sclerosis].
    Mathiesen HK; Sørensen PS
    Ugeskr Laeger; 2014 Jan; 176(3A):V06130416. PubMed ID: 25347174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.
    Fragoso YD; Adoni T; Alves-Leon SV; Apostolos-Pereira SL; Barreira AA; Brooks JB; Claudino R; Correa EC; Ferreira ML; Finkelsztejn A; Finkelsztejn J; da Gama PD; Goncalves MV; Guerreiro CT; da Cunha Matta AP; Marques VD; Rizo Morales R; Parolin MF; de Castro Ribeiro M; Ribeiro TA; Ruocco HH; Sato H; Scherpenhuijzen S; Siquineli F; de Carvalho Sousa NA; Varela DL; Tauil CB; Winckler TC
    NeuroRehabilitation; 2016 Jun; 39(2):301-4. PubMed ID: 27372365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
    Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
    Savin Z; Lejbkowicz I; Glass-Marmor L; Lavi I; Rosenblum S; Miller A
    J Neurol Sci; 2016 Jan; 360():102-9. PubMed ID: 26723984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review.
    Behm K; Morgan P
    Disabil Rehabil; 2018 Jul; 40(15):1733-1744. PubMed ID: 28376639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.
    Weller D; Lörincz L; Sutter T; Reuter K; Linnebank M; Weller M; Zörner B; Filli L
    J Neurol Sci; 2020 Sep; 416():116978. PubMed ID: 32559515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study.
    Valet M; El Sankari S; Van Pesch V; Detrembleur C; Lejeune T; Stoquart G
    Clin Biomech (Bristol); 2021 Jun; 86():105382. PubMed ID: 34000628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
    Lo AC; Ruiz JA; Koenig CM; Anderson BM; Olson KM; Triche EW
    J Neurol Sci; 2015 Sep; 356(1-2):77-82. PubMed ID: 26139339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
    Morrow SA; Rosehart H; Johnson AM
    Mult Scler Relat Disord; 2017 Jan; 11():4-9. PubMed ID: 28104253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis.
    Ghorbanpour S; Rahimibarghani S; Rohani S; Rastkar M; Ghajarzadeh M
    Neurol Sci; 2023 Sep; 44(9):3059-3069. PubMed ID: 37055710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical response and tolerability of fampridine in clinical practice.
    Costa-Arpín E; Pato A; Rodríguez-Regal A; Midaglia L; Yáñez R; Muñoz D; Lorenzo JR; Amigo C; Prieto JM
    Neurodegener Dis Manag; 2016 Apr; 6(2):99-105. PubMed ID: 27032814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
    Pavsic K; Pelicon K; Ledinek AH; Sega S
    Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; Lechner-Scott J; Gaebler JA; Agarwal S; Wang P; Yeh M; Hovenden M; Soelberg Sørensen P
    Mult Scler; 2016 Jun; 22(7):944-54. PubMed ID: 26447066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
    Preiningerova JL; Baumhackl U; Csepany T; Czaplinski A; Deisenhammer F; Derfuss T; Fabjan TH; Fazekas F; Fuchs S; Havrdova E; Ledinek AH; Illes Z; Jazbec SS; Klimova E; Komoly S; Kurca E; Linnebank M; Lisy L; Mares J; Prochazkova L; Csilla R; Szilasiova J; Stourac P; Talab R; Turcani P; Vachova M; Vecsei L; Vodusek D; Zapletalova O; Berger T
    CNS Neurosci Ther; 2013 May; 19(5):302-6. PubMed ID: 23607697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fampridine: Long-term benefits in walking in multiple sclerosis.
    Bennett SE
    Neurology; 2017 Feb; 88(9):818-819. PubMed ID: 28148627
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.